KRTX - Karuna Therapeutics Says Its Antipsychotic Candidate Shows Favorable Cardiovascular Safety Profile In Schizophrenia Patients | Benzinga
Karuna Therapeutics Inc (NASDAQ: KRTX) released results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood pressure in adults with schizophrenia.
The data demonstrated that KarXT was not associated with increases in blood pressure.
Also Read: What Are Latest Investor Thoughts On Karuna Therapeutics? Analyst Sees Buying Opportunity.
The primary endpoint in the trial ...